Today's Pod discusses...
1) A large trial comparing 4 different CLL treatments
GAIA-CLL13: https://www.nejm.org/doi/full/10.1056/NEJMoa2213093
2)Adding Cabozantinib + Nivo/Ipo vs. Nivo/Ipi in intermediate/poor risk mRCC
COSMIC-313: https://www.nejm.org/doi/full/10.1056/NEJMoa2212851
3) A potential future biomarker for predicting response to PD-(L)1 targeted therapies
Functional PD-1/PD-L1 Engagement: https://pubmed.ncbi.nlm.nih.gov/?term=36821809